Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Status:
Active, not recruiting
Trial end date:
2022-01-30
Target enrollment:
Participant gender:
Summary
This research study is designed to see if a drug called Nivolumab is effective in treating
patients with advanced refractory biliary tract cancers. Nivolumab has been approved by the
U.S. Food and Drug Administration (FDA) for treatment of certain types of cancer but is not
approved by the FDA for treatment of your type of cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute